

SERRIN[®] TABLET

Description

Orange, convex round enteric film-coated tablets with letters "AM 005" in black colour on one side.

Pharmacodynamics

1. Suppresses the fibrinolysis activity and increases vascular permeability.
2. Strongly hydrolyses bradykinin, a phlogistic polypeptide.
3. Strongly lyzes fibrin and fibrinogen, but does not appreciably affect proteins in the living body. E.g. albumin and alpha and gamma globulins.

Pharmacokinetics

1. Inflammatory edema and swelling elimination: It increases the circulation at the focal site by breaking down abnormal protein and exudates and increases the absorption of the decomposed products through the blood and lymphatic vessels.
2. Acceleration of elimination of sputum, pus and haematoma: It decreases the dry weight and viscosity by breaking down and liquefying mucous secretions and fibrin clots.
3. Increases antibiotic actions: It increases the transfer and concentration of antibiotics in the blood and to the infectious site.

Indication

As an adjunctive therapy in:

1. Inflammation after operation and traumatic injury
2. Inflammation in the following diseases: sinusitis, engorgement of the breast, cystitis and epididymitis, pericoronitis of the wisdom tooth and alveolar abscess.
3. Difficulty of expectoration of sputum in respiratory tract diseases and after anaesthesia.

Recommended dose

1 to 2 tablets taken three times a day after meals without chewing. Dosage may increase according to condition.

Route of Administration: Oral

Contraindications

Known hypersensitivity to Serratiopeptidase.

Warnings and Precautions

Administration should be careful in patients with blood coagulation disorder and severe hepatic or renal disorder.

Interactions with other medications

Serratiopeptidase with anticoagulant may intensify the anticoagulant effect. It should be administered cautiously under close observation.

Pregnancy and lactation

No data available for the use of Serratiopeptidase in pregnancy and lactation. Avoid the use of Serrin[®] Tablets in such cases.

Side effects

Rash, redness, diarrhoea and gastric discomfort may occur. Discontinue use if these symptoms occur.

Symptoms and treatment of overdose

In the event of an overdosage, the stomach may be emptied and symptomatic treatment should be given.

Storage condition

Store below 30°C. Protect from light and moisture.

Shelf life

3 years

Pack size

Box of 500 tablets (50 x 10's printed aluminium foil – transparent PVC blister)

Manufactured by

MacroPhar Co. Ltd.
89 Soi Patanakarn 20 Yaek 4,
Patanakarn Road,
Bangkok 10250, Thailand
Tel: (662)314 6671; Fax: (662) 318 6091

Product Registration Holder

Healol Pharmaceuticals Sdn. Bhd.
74-3 Jalan WangsaDelima 6, KLSC WangsaMaju,
53300 Kuala Lumpur, Malaysia
Tel: 03-4142 7106. 7107; Fax: 03-4149 8108

Date of revision of package insert

April 2019